Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.32 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14773916 | 0.91 | TSHR (0.33) | TSHRAKR1B1MAPTMEN1ALDH1A1 | |
| SCHEMBL9976554 | 0.90 | DPP4 (0.40) | MAPTMEN1ALDH1A1KMT2ATP53 | |
| SCHEMBL14773879 | 0.85 | TP53 (0.34) | KMT2ATP53 | |
| SCHEMBL14646183 | 0.84 | KMT2A (0.38) | AKR1B1MAPTMEN1ALDH1A1HTT | |
| SCHEMBL14646212 | 0.84 | KMT2A (0.38) | AKR1B1MAPTMEN1ALDH1A1HTT | |
| SCHEMBL14645928 | 0.82 | KEAP1 (0.36) | DAOAKR1B1MAPTMEN1ALDH1A1 | |
| SCHEMBL14645296 | 0.82 | POLB (0.41) | MEN1ALDH1A1KMT2ARPS6KB2 | |
| SCHEMBL14646131 | 0.82 | POLB (0.41) | MEN1ALDH1A1KMT2ARPS6KB2 | |
| SCHEMBL14773967 | 0.82 | GABRP (0.35) | AKR1B1MAPTMEN1ALDH1A1HTT | |
| SCHEMBL14773880 | 0.82 | SRC (0.36) | AKR1B1MAPTMEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710246-B2 | Substituted thiophene pentamers | BIOCHROMIX NEWCO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-8710246-B2 | Substituted thiophene pentamers | BIOCHROMIX NEWCO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2012-06-21 | — | — | US | disclosed |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2012-06-21 | — | — | US | disclosed |
| WO-2010044744-A1 | NOVEL THIOPHENE COMPOUNDS FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010044743-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPHY | BIOCHROMIX PHARMA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | HSPE1, TTR, HTT | DAO 3336/4885PDE4B 3592/4885PDE4D 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.